Travere Therapeutics - TVTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.00
  • Forecasted Upside: 48.09 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$27.01
▼ -0.76 (-2.74%)

This chart shows the closing price for TVTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Travere Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TVTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TVTX

Analyst Price Target is $40.00
▲ +48.09% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is $40.00, with a high forecast of $45.00 and a low forecast of $35.00. The average price target represents a 48.09% upside from the last price of $27.01.

This chart shows the closing price for TVTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Travere Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2022Piper SandlerLower Target$41.00 ➝ $39.00Low
8/9/2022Evercore ISILower Target$35.00Low
8/9/2022BarclaysLower Target$37.00Low
8/8/2022HC WainwrightLower TargetBuy$46.00 ➝ $42.00Low
8/5/2022SVB LeerinkBoost TargetOutperform$42.00 ➝ $45.00Low
7/26/2022Piper SandlerBoost TargetOverweight$40.00 ➝ $41.00Low
7/14/2022Canaccord Genuity GroupReiterated RatingBuy$42.00Low
5/17/2022HC WainwrightBoost TargetBuy$45.00 ➝ $46.00N/A
5/6/2022Piper SandlerLower Target$42.00 ➝ $40.00High
3/30/2022Piper SandlerInitiated CoverageOverweight$42.00Medium
2/28/2022HC WainwrightInitiated CoverageBuy$45.00Medium
12/16/2021BarclaysBoost TargetOverweight$36.00 ➝ $40.00Medium
12/16/2021SVB LeerinkBoost TargetOutperform$37.00 ➝ $42.00Medium
8/17/2021SVB LeerinkBoost TargetOutperform$27.00 ➝ $37.00High
6/6/2021SVB LeerinkReiterated RatingBuyLow
5/26/2021SVB LeerinkBoost TargetOutperform$27.00 ➝ $35.00High
5/26/2021Evercore ISILower TargetOutperform$30.00 ➝ $23.00High
5/26/2021WedbushDowngradeOutperform ➝ Neutral$19.00High
5/26/2021BarclaysLower TargetOverweight$40.00 ➝ $34.00High
5/7/2021BMO Capital MarketsLower TargetOutperform$43.00 ➝ $38.00High
4/12/2021WedbushLower TargetOutperform$46.00 ➝ $39.00High
3/3/2021SVB LeerinkReiterated RatingOutperformHigh
3/2/2021BMO Capital MarketsLower Target$48.00 ➝ $43.00High
2/3/2021BMO Capital MarketsBoost TargetPositive ➝ Outperform$33.00 ➝ $48.00High
11/23/2020Evercore ISIInitiated CoverageOutperformMedium
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/19/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/21/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/20/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/20/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 3 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Travere Therapeutics logo
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $27.01
Low: $26.69
High: $27.67

50 Day Range

MA: $24.94
Low: $22.38
High: $28.63

52 Week Range

Now: $27.01
Low: $19.42
High: $31.65

Volume

31,810 shs

Average Volume

828,505 shs

Market Capitalization

$1.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Travere Therapeutics?

The following Wall Street analysts have issued reports on Travere Therapeutics in the last year: Barclays PLC, Canaccord Genuity Group Inc., Evercore ISI, HC Wainwright, Piper Sandler, and SVB Leerink LLC.
View the latest analyst ratings for TVTX.

What is the current price target for Travere Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Travere Therapeutics in the last year. Their average twelve-month price target is $40.00, suggesting a possible upside of 48.1%. SVB Leerink LLC has the highest price target set, predicting TVTX will reach $45.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $35.00 for Travere Therapeutics in the next year.
View the latest price targets for TVTX.

What is the current consensus analyst rating for Travere Therapeutics?

Travere Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TVTX will outperform the market and that investors should add to their positions of Travere Therapeutics.
View the latest ratings for TVTX.

What other companies compete with Travere Therapeutics?

How do I contact Travere Therapeutics' investor relations team?

Travere Therapeutics' physical mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The company's listed phone number is (888) 969-7879 and its investor relations email address is [email protected] The official website for Travere Therapeutics is www.retrophin.com. Learn More about contacing Travere Therapeutics investor relations.